Legal & General Group Plc Grows Stake in Corteva, Inc. $CTVA

Key Points

• Legal & General Group Plc boosted its Corteva stake by 14.3% in Q3, adding 720,469 shares to hold 5,753,982 shares (about 0.85% of the company), valued at roughly $389.1 million.
• Analyst sentiment has firmed, with multiple firms raising targets and the consensus rating at a “Moderate Buy” and an average price target of $82.90.
• Corteva reported Q results with EPS of $0.22 (in line with estimates) but revenue of $3.91B missed expectations, and management set FY‑2026 guidance of $3.45–$3.70 EPS.

Legal & General Group Plc lifted its stake in shares of Corteva, Inc. (NYSE:CTVA - Free Report) by 14.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,753,982 shares of the company's stock after purchasing an additional 720,469 shares during the period. Legal & General Group Plc owned 0.85% of Corteva worth $389,142,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Norges Bank bought a new position in Corteva during the second quarter valued at $434,220,000. Pacer Advisors Inc. raised its stake in shares of Corteva by 4,007.1% in the third quarter. Pacer Advisors Inc. now owns 2,442,177 shares of the company's stock valued at $165,164,000 after buying an additional 2,382,715 shares during the period. Marshall Wace LLP lifted its position in shares of Corteva by 1,365.9% during the 2nd quarter. Marshall Wace LLP now owns 1,809,764 shares of the company's stock valued at $134,882,000 after buying an additional 1,686,309 shares during the last quarter. National Pension Service grew its stake in shares of Corteva by 148.4% during the 2nd quarter. National Pension Service now owns 2,454,601 shares of the company's stock worth $182,941,000 after acquiring an additional 1,466,268 shares during the period. Finally, Qube Research & Technologies Ltd increased its holdings in Corteva by 566.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,247,120 shares of the company's stock worth $92,948,000 after acquiring an additional 1,059,872 shares during the last quarter. Institutional investors own 81.54% of the company's stock.

Analysts Set New Price Targets

CTVA has been the topic of several recent research reports. The Goldman Sachs Group reaffirmed a "buy" rating and set a $88.00 price objective on shares of Corteva in a report on Thursday, February 5th. Royal Bank Of Canada boosted their price target on shares of Corteva from $80.00 to $89.00 and gave the company an "outperform" rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. downgraded shares of Corteva from an "overweight" rating to a "neutral" rating and raised their price objective for the stock from $75.00 to $77.00 in a report on Thursday, February 5th. Wells Fargo & Company increased their target price on Corteva from $77.00 to $85.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Finally, BNP Paribas Exane raised their price target on Corteva from $72.00 to $74.00 in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $82.90.

Corteva Price Performance

CTVA stock opened at $78.65 on Thursday. The firm has a 50 day moving average of $73.63 and a 200-day moving average of $69.13. The firm has a market capitalization of $52.89 billion, a P/E ratio of 49.78, a price-to-earnings-growth ratio of 2.61 and a beta of 0.72. Corteva, Inc. has a 12 month low of $53.40 and a 12 month high of $80.90. The company has a current ratio of 1.43, a quick ratio of 0.96 and a debt-to-equity ratio of 0.07.

Corteva (NYSE:CTVA - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, hitting analysts' consensus estimates of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same quarter in the prior year, the firm posted $0.32 EPS. Corteva's revenue was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, sell-side analysts predict that Corteva, Inc. will post 2.96 earnings per share for the current fiscal year.

Corteva Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be paid a dividend of $0.18 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $0.72 annualized dividend and a yield of 0.9%. Corteva's dividend payout ratio (DPR) is currently 45.57%.

Insider Transactions at Corteva

In other Corteva news, insider Brian Titus sold 8,311 shares of the company's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the transaction, the insider directly owned 8,090 shares in the company, valued at $619,289.50. This represents a 50.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.14% of the company's stock.

Corteva Company Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.